Wells Fargo Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) on January 10 and set a price target ...
Travere Therapeutics Provides Corporate Update and 2025 Outlook
Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net ...
Seeking Alpha25d
Travere Therapeutics: Cautiously Bullish Based On Improving Revenue
Travere Therapeutics' sparsentan received full FDA approval for IgA nephropathy, showing long-term kidney function preservation and significant market growth, with $35mn in 3Q24 revenues.
Eagle-Tribune1mon
Sparsentan receives Orphan Drug Designation for primary IgA nephropathy in Japan
TOKYO, Dec. 2, 2024 /PRNewswire/ -- Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. ("Travere") and ...
Yahoo Finance1mon
Sparsentan receives Orphan Drug Designation for primary IgA nephropathy in Japan
TOKYO, Dec. 2, 2024 /PRNewswire/ -- Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. ("Travere") and ...
Armed robbery in Revesby1mon
Sparsentan Approved for Adult IgAN Treatment
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sparsentan (Filspari) to treat primary immunoglobulin A nephropathy (IgAN). IgA neuropathy, also known as ...